SENSEX
NIFTY
GOLD
USD/INR

Weather

image 17    C

Health & Fitness News

The Economic Times

Health & Fitness / The Economic Times

details

Dr Reddy's bets on generic semaglutide, biosimilars

Dr Reddy's domestic formulations business grew in the September quarter, while Revlimid sales declined in North America. A relaunch of generic semaglutide and the US launch of abatacept biosimilar are anticipated for future growth. The company aims to sell millions of pens for semaglutide with a focus on international markets. Furthermore, an expanding biosimilars portfolio aims to strengthen its position beyond traditional generics.

26 Oct 2026 1:19 am